KRAS and cancer: For example, the KRYSTAL-10 and LOXO 101 trials were both active in Ireland: KRYSTAL-10 recruited at several Irish hospitals and investigated the use of a novel KRAS-inhibiting drug, adagrasib, to treat colorectal cancer patients who have the KRAS-activating G12C mutation136, while LOXO 101 investigated the use of larotrectinib to treat any cancer harbouring anNTRK gene fusion that has been confirmed via molecular assay137.